Apollo Capital Partners has struck a deal to purchase a minority interest in McKesson’s medical‑surgical solutions unit. The transaction values the MMS business at roughly $13 billion, with Apollo paying $1.25 billion for its stake. McKesson, headquartered in Irving, Texas, will keep majority ownership and retain full operational control. The partnership aims to combine Apollo’s capital expertise with McKesson’s extensive distribution network across.

MMS supplies hospitals and surgery centers with a broad catalog of disposable instruments, implants and related services. By bringing in a private‑equity partner, McKesson can fund growth initiatives without diluting its control. The infusion also signals confidence in the profitability of the medical‑surgical segment, which has shown steady demand despite broader healthcare cost pressures. Analysts view it as margin validation.

For shareholders, the deal translates into immediate cash inflow while preserving McKesson’s strategic direction in a high‑growth arena. Apollo’s minority position grants it exposure to a stable revenue stream without assuming operational risk. The structure underscores a trend where large healthcare distributors partner with financial investors to unlock value without surrendering core governance and maintain long‑term competitive advantage for the.